Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
- How it’s given
- “4 intradermal injections of 1 ml containing 25e6 cells + 2 injection of 0,4 ml containing 10e6 cells”In the company’s words, NCT07651878 on ClinicalTrials.gov
- Tested for
- CML (Chronic Myelogenous Leukemia)
- Main trialPhase 1
- “The main purpose of the trial is to evaluate the safety and potential side effects of cell therapy vididencel in Chronic Myeloid Leukemia (CML) participants with measurable residual disease (MRD) unable to stop treatment with tyrosine kinase inhibitor (TKI). Patients may not receive any direct medical benefit from participating. Participants in the study should have been treated with TKI for at least 24 months prior to enrolment. This TKI must be of the same type throughout the 24 months. Participation in the active period of the study will take about 5 months after which patients will be…”In the company’s words, NCT07651878 on ClinicalTrials.gov
Other drugs for CML (Chronic Myelogenous Leukemia)
- OlverembatinibAscentage Pharma Group Inc. · Phase 3
- Radotinib HClIl-Yang Pharm. Co., Ltd. · Phase 3
- ELVN-001Enliven Therapeutics · Phase 3
- HS-10382Hansoh · Phase 3
- TGRX-678TargetRx · Phase 3
- PonatinibTakeda · Phase 1/2
Coming up1
- 1 Sep 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 1 Sep 2029 | Vididencel in CML-CP Patients With MRD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026